Supplement. Obesity, hypertension, insulin resistance and lipid disorders: Cross-sectional and longitudinal studies in Japanese adolescents and middle-aged men

Internal Medicine

Volumn 38, Issue 2, 1999, Pages 198-200

  Hirose, Hiroshi ^a   Saito, Ikuo ^a   Saruta, Takao ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Adolescent; Leptin

Indexed keywords

CHOLESTEROL; INSULIN; LEPTIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; BASAL METABOLIC RATE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032969786     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.198     Document Type: Conference Paper

References (16)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
2. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194, 1991.
3. Anderson EA, Mark AL. The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension 21: 136-141, 1993 (published erratum appears in Hypertension 21: 745, 1993) (editorial, comment).
4. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 25: 893-897, 1995.
5. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994 (published erratum appears in Nature 374: 479, 1995) (see comments).
6. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obses gene. Science 269: 543-546, 1995 (see comments).
7. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263-1271, 1995.
8. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292-295, 1996 (see comments).
9. Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, Haynes WG. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 138: 3395-3401, 1997.
10. Koyama K, Chen G, Wang MY, et al. Beta-cell function in normal rats made chronically hyperleptinemic by adenovirus-leplin gene therapy. Diabetes 46: 1276-1280, 1997.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
12. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 153: 154-183, 1993 (see comments).
13. Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, Surwit RS. Role of leptin in fat regulation. Nature 380: 677, 1996 (letter).
14. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 100: 270-278, 1997.
15. Reams G, Villarreal D, Taraben A, Freeman RH, Knoblich P: Renal effects of leptin in normotensive and spontaneously hypertensive rats. FASEB J 11: A258, 1997.
16. Swislocki A. Insulin resistance and hypertension. Am J Med Sci 300: 104-115, 1990.